EA032762B1 - Твердые составы, содержащие омега-3 и ресвератрол - Google Patents

Твердые составы, содержащие омега-3 и ресвератрол Download PDF

Info

Publication number
EA032762B1
EA032762B1 EA201692399A EA201692399A EA032762B1 EA 032762 B1 EA032762 B1 EA 032762B1 EA 201692399 A EA201692399 A EA 201692399A EA 201692399 A EA201692399 A EA 201692399A EA 032762 B1 EA032762 B1 EA 032762B1
Authority
EA
Eurasian Patent Office
Prior art keywords
omega
pufas
composition according
resveratrol
diseases
Prior art date
Application number
EA201692399A
Other languages
English (en)
Russian (ru)
Other versions
EA201692399A1 (ru
Inventor
Джузеппе Джаннини
Мозе Сантаньелло
Original Assignee
Альфасигма С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Альфасигма С.П.А. filed Critical Альфасигма С.П.А.
Publication of EA201692399A1 publication Critical patent/EA201692399A1/ru
Publication of EA032762B1 publication Critical patent/EA032762B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
EA201692399A 2014-06-04 2015-03-26 Твердые составы, содержащие омега-3 и ресвератрол EA032762B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14001940.7A EP2952180B1 (en) 2014-06-04 2014-06-04 Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)
PCT/EP2015/056530 WO2015185239A1 (en) 2014-06-04 2015-03-26 Solid formulations containing omega-3 and resveratrol

Publications (2)

Publication Number Publication Date
EA201692399A1 EA201692399A1 (ru) 2017-03-31
EA032762B1 true EA032762B1 (ru) 2019-07-31

Family

ID=50884650

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692399A EA032762B1 (ru) 2014-06-04 2015-03-26 Твердые составы, содержащие омега-3 и ресвератрол

Country Status (14)

Country Link
US (1) US20170112791A1 (cg-RX-API-DMAC7.html)
EP (1) EP2952180B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017522278A (cg-RX-API-DMAC7.html)
CN (1) CN106456587B (cg-RX-API-DMAC7.html)
AU (1) AU2015271278A1 (cg-RX-API-DMAC7.html)
CA (1) CA2943021A1 (cg-RX-API-DMAC7.html)
EA (1) EA032762B1 (cg-RX-API-DMAC7.html)
ES (1) ES2615630T3 (cg-RX-API-DMAC7.html)
MX (1) MX369782B (cg-RX-API-DMAC7.html)
PL (1) PL2952180T3 (cg-RX-API-DMAC7.html)
PT (1) PT2952180T (cg-RX-API-DMAC7.html)
SI (1) SI2952180T1 (cg-RX-API-DMAC7.html)
UA (1) UA119174C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015185239A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034124A1 (en) * 2007-09-12 2009-03-19 Novozymes A/S Omega-3 stabilisation towards oxidation
US20100247632A1 (en) * 2009-03-24 2010-09-30 Dong Liang C Stabilized solubility-enhanced formulations for oral delivery
WO2011120530A1 (en) * 2010-03-31 2011-10-06 Lifecycle Phama A/S Porous tablets as carriers for liquid formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384548C (zh) * 2002-08-14 2008-04-30 索莱有限责任公司 具有高液体负载的固体易流动粉末
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
EA201200935A1 (ru) 2009-12-23 2012-12-28 Дефианте Фармасеутика С.А. Комбинированная композиция, подходящая для лечения сердечно-сосудистых заболеваний
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
EP3488847B1 (en) * 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034124A1 (en) * 2007-09-12 2009-03-19 Novozymes A/S Omega-3 stabilisation towards oxidation
US20100247632A1 (en) * 2009-03-24 2010-09-30 Dong Liang C Stabilized solubility-enhanced formulations for oral delivery
WO2011120530A1 (en) * 2010-03-31 2011-10-06 Lifecycle Phama A/S Porous tablets as carriers for liquid formulations

Also Published As

Publication number Publication date
UA119174C2 (uk) 2019-05-10
CA2943021A1 (en) 2015-12-10
SI2952180T1 (sl) 2017-05-31
MX2016013189A (es) 2017-01-16
AU2015271278A1 (en) 2016-11-10
PT2952180T (pt) 2017-03-02
EP2952180B1 (en) 2017-01-25
PL2952180T3 (pl) 2017-05-31
WO2015185239A1 (en) 2015-12-10
ES2615630T3 (es) 2017-06-07
CN106456587B (zh) 2020-03-20
US20170112791A1 (en) 2017-04-27
CN106456587A (zh) 2017-02-22
EP2952180A1 (en) 2015-12-09
EA201692399A1 (ru) 2017-03-31
JP2017522278A (ja) 2017-08-10
MX369782B (es) 2019-11-21

Similar Documents

Publication Publication Date Title
RU2709612C2 (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
EP3248599B1 (en) Omega-3 fatty acid self-emulsifying composition
CN102843922B (zh) 硝基脂肪酸–认知减退的神经保护和/或抑制
JP5827784B2 (ja) ビタミンｋ２を含む医薬及び栄養補助製品
ES2889874T3 (es) Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas
CN115666548A (zh) 富含lpc-dha和lpc-epa的磷虾油组合物
WO2024109560A1 (zh) 一种高稳定性脂质体及其制备方法和用途
CN101888837B (zh) 提高辅酶q10生物利用度的辅酶q10和大蒜油的组合物
JP6552526B2 (ja) ω−３多価不飽和脂肪酸及びレスベラトロールを含む経口投与用均質処方物
JP6750831B2 (ja) 非アルコール性脂肪性肝疾患の処置
EA032762B1 (ru) Твердые составы, содержащие омега-3 и ресвератрол
WO2020008359A1 (en) A formulation for the prevention and as a coadjuvant treatment of neurodegenerative diseases
RU2851882C1 (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
Moschetti Formulation and characterization of bioactive lipid containing reconstituted high density lipoproteins
Koga Stabilization of resveratrol through microencapsulation and incorporation into food products

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM